Search

Displaying results 2131 - 2140 of 10000 in total
  1. Target

    Short transient receptor potential channel 6

    go.drugbank.com/bio_entities/BE0020965
    TargetHumans

    Mediates calcium entry following G(q)-coupled receptor or receptor tyrosine kinase activation, which triggers phospholipase C (PLC)-mediated hydrolysis of phosphatidylinositides and production of diacylglycerol

    Polypeptides: Short transient receptor potential channel 6Synonyms: Transient receptor protein 6
  2. Target

    Neuropeptide Y receptor type 4-2

    go.drugbank.com/bio_entities/BE0024014
    TargetHumans

    G protein-coupled receptor for PPY/pancreatic polypeptide/PP, NPY/neuropeptide Y and PYY/peptide YY that is negatively coupled to cAMP.

    Polypeptides: Neuropeptide Y receptor type 4-2Function: pancreatic polypeptide receptor activity
  3. Target

    T cell receptor gamma variable 9

    go.drugbank.com/bio_entities/BE0025222
    TargetHumans

    V region of the variable domain of T cell receptor (TR) gamma chain that participates in the antigen recognition (PubMed:24600447).

    Polypeptides: T cell receptor gamma variable 9
  4. Drug

    Elapegademase

    go.drugbank.com/drugs/DB14712
    Approved

    It can be defined molecularly as a genetically modified bovine adenosine deaminase with a modification in cysteine 74 for serine and with about 13 methoxy polyethylene glycol chains bound via carbonyl … group in alanine and lysine residues.

    Synonyms: (74-SERINE (C>S),245-THREONINE (A>T))BOS TAURUS ADENOSINE DEAMINASE (BOVINE ADENOSINE AMINOHYDROLASE, EC=3.5.4.4)-(1-356)-PEPTIDE PRODUCED IN ESCHERICHIA COLI, AN AVERAGE OF 13 RESIDUES ARE SUBSTITUTED, AN AVERAGE OFAPPROXIMATELY 13 .OMEGA.
  5. Drug

    Quinacrine

    go.drugbank.com/drugs/DB01103
    Investigational

    An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. … It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.

  6. Drug

    Simeprevir

    go.drugbank.com/drugs/DB06290
    ApprovedWithdrawn

    According to 2017 American Association for the Study of Liver Diseases (AASLD) and 2015 consensus guidelines from the Canadian Association for the Study of the Liver (CASL), simeprevir can be used as first-line … Broad use of simeprevir occurred when it was used in combination with a newer drug, [DB08934].

  7. Drug

    Parsaclisib

    go.drugbank.com/drugs/DB14867
    Investigational

    Parsaclisib is under investigation in clinical trial NCT03126019 (An Open-Label Study of Parsaclisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)).

  8. Drug

    Albiglutide

    go.drugbank.com/drugs/DB09043
    ApprovedInvestigationalWithdrawn

    Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). … It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA.

    Categories: Drugs Used in Diabetes
  9. Drug

    Benserazide

    go.drugbank.com/drugs/DB12783
    ApprovedInvestigational

    A decarboxylase inhibitor like benserazide is consequently an effective compound to combine with levadopa as it is incapable of crossing the blood-brain barrier itself but acts to prevent the formation … This can result in a number of side effects like nausea, vomiting, or even cardiac arrhythmias that may diminish patient adherence [F2, L2553].

  10. Drug

    Finerenone

    go.drugbank.com/drugs/DB16165
    ApprovedInvestigational

    [A236544] Spironolactone has low selectivity and affinity for the receptor; it dissociates quickly and can also have effects at the androgen, progesterone, and glucocorticoid receptors. … Finerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart

    Categories: Mineralocorticoid Receptor Antagonists, Nonsteroidal Mineralocorticoid-Receptor Antagonist